Fig 9.

Effects of 1 in combination with remdesivir in Vero-E6 cells following 4-day infection with SARS-CoV-2 (USA-WA1/2020 variant). Assays were performed as described in Fig. 7. (A) Representative brightfield images of infected cells following 4-day incubation in the absence or presence of remdesivir and/or 1. Scale bars = 100 µm. (B) Dose-response curves of compound 1 (x-axis) in the presence of 1 or 3 µM remdesivir. Treatment with 5 µM of 1 plus 1 µM of remdesivir significantly inhibits SARS-CoV-2-induced CPE relative (asterisk), as measured using the Bliss independence model, when compared to cells treated with 1 alone (triangles) or remdesivir alone (left-most values). Data are presented as percent virus inhibition, with 0% denoting the viability of infected cells without drug and 100% denoting the viability of uninfected cells.